Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

Immunotherapies may increase risk of severe COVID-19 in MS patients as total MS drug market in the 7MM set to reach $32.9bn by 2028

COVID-19 presents a challenge to physicians managing patients with multiple sclerosis (MS), due to concerns about using immunotherapies to treat this neurological condition, in the face of the pandemic, says GlobalData, a leading data and analytics company. Immunotherapies are the biggest driver in the MS market and according to GlobalData’s report, ‘Multiple Sclerosis – Global Drug Forecast […]
Read more

Gilead’s remdesivir gets MHRA green light, but only targets select group of COVID-19 patients

GlobalData anticipates that Gilead’s remdesivir will target a select severity group of COVID-19 patients, and it remains questionable as to how treatment with the drug will be initiated and optimized.  Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData, states: “Gilead’s remdesivir was trialled in a number of patients with varying severities, however, it was noted […]
Read more

COVID-19 may have long-term complications and increased long-term costs on the healthcare system

As many COVID-19 patients may experience long-term complications from the illness such as intensive care unit (ICU) delirium, post-traumatic stress disorder (PTSD), lung damage, heart damage and possible neurological issues, GlobalData expects the market for these treatments to increase due to the COVID-19 pandemic as recovered patients may need long-term care for these issues after being released […]
Read more

CCR4 antagonists are a promising combinatorial agent for the future

As novel immuno-oncology (IO) drugs become established in the market, a new trend of combinatorial treatments is arising. The race to develop combinatorial drugs is increasing with more companies including IO potentiating drugs in their pipelines and investigating these in combination with established IO drugs, says GlobalData, a leading data and analytics company. Miguel Ferreira, […]
Read more

Contact tracing apps fail the most vulnerable in society

The UK’s contact tracing application is inaccessible to 21% of the adult population who do not use the latest smartphones. The pandemic has exposed a digital divide where the poorest and oldest in society have limited access to the latest technology, says GlobalData, a leading data and analytics company. Oliver Lockett, Analyst at GlobalData, comments: […]
Read more

Pharmaceutical software development less disrupted by COVID-19

Pharmaceutical software development has been less impacted by the COVID-19 crisis as it facilitates remote working and already had group collaboration tools and software processes in place to facilitate this type of work, says GlobalData, a leading data and analytics company.  Johanna Swanson, Product Manager at GlobalData, comments: “Numerous Software development systems have adopted a more […]
Read more

COVID-19 has impacted dental procedures in the US

Non-emergency dental procedures such as alveoloplasty, incision and excision of gums, and the removal or restoration of teeth are mostly elective and will substantially impacted by the COVID-19 crisis in the US, says GlobalData, a leading data and analytics company. Eric Chapman, Medical Analyst at GlobalData, comments: “Healthcare providers performing dental procedures are at high […]
Read more

Once again, M&S finds slow and steady does not win the race

Following today’s release of Marks & Spencer FY figures for 2019/20, Sofie Willmott, Lead Retail Analyst at GlobalData, a leading data and analytics company, comments: ‘‘Despite M&S working through its transformation plan over the last few years, its UK performance continued to deteriorate in FY2019/20 and since then COVID-19 has caused sales to nosedive (down […]
Read more

Moderna’s and Inovio’s Phase III COVID-19 trials face operational obstacles

Following the announcement of Moderna’s interim data for its Phase I COVID-19 vaccine trial; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “Moderna’s registrational trial will face substantial operational challenges, despite having a low success bar for efficacy. Moderna, which stocks shot up almost 30% premarket in reaction to today’s […]
Read more

COVID-19 pandemic and opioid use disorder epidemic could impact and worsen each other

COVID-19 pandemic and opioid use disorder (OUD) are intersecting and worsening each other, demanding a rapid response to correct the underlying factors, says GlobalData, a leading data and analytics company. Arunkumar NV, Epidemiologist at GlobalData, comments “Impaired psychosocial wellbeing, due to unstable socio-economic situations and disrupted opioid addiction treatment schedules, will cause an increasing wave […]
Read more
1 … 11 12 13 14 15